drugset / Trial / NCT07475546
Combination Gerotherapeutic Interventions for Healthspan Improvement
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).
Timeline
- Start
- 2025-07-23
- Primary completion
- 2026-04
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSH | Unknown | — | Topical |
| Subject | Metformin | Small molecule | 500 mg | — |
| Subject | Naltrexone | Small molecule | 4.5 mg | — |
| Subject | Sirolimus | Small molecule | 6 mg | — |
| Subject | nicotinamide adenine dinucleotide (NAD+) | Unknown | 30 mg | Intranasal |
Indications
No indication recorded.